ANSM
- Local brand name: Augtyro
- Status: approved
Augtyro (REPOTRECTINIB) regulatory status in France.
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. ANSM has authorised it.
Bristol is the originator. The local marketing authorisation holder may differ — check the official source linked above.